Foghorn Therapeutics Inc. | Small-cap | Healthcare
$4.90
0.62%
| Foghorn Therapeutics Stock Comparison:
Foghorn Therapeutics vs VertexFoghorn Therapeutics vs RegeneronFoghorn Therapeutics vs Alpha Tau MedicalFoghorn Therapeutics vs CartesianFoghorn Therapeutics vs Tevogen Bio HoldingsFoghorn Therapeutics vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 22.6M
Operating Income -100.3M -443.70%
Net Income -86.6M -383.24%

Balance Sheet Metrics

Total Assets 284.0M
Total Liabilities 329.5M
Shareholders Equity -45.5M

Cash Flow Metrics

Operating Cash Flow -98.9M
Free Cash Flow -101.3M

Revenue & Profitability Trend

Foghorn Therapeutics Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 22.6M 34.2M 19.2M 1.3M 430.0K
Cost of Goods Sold - - - - -
Gross Profit - - - - -
Operating Expenses 122.9M 142.1M 136.4M 102.1M 69.0M
Operating Income -100.3M -107.9M -117.1M -100.7M -68.5M
Pre-tax Income -86.6M -94.2M -108.9M -101.3M -68.8M
Income Tax 0 4.2M 0 - -
Net Income -86.6M -98.4M -108.9M -101.3M -68.8M
EPS (Diluted) - -$2.34 -$2.62 -$2.73 -$6.23

Income Statement Trend

Foghorn Therapeutics Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 249.6M 240.2M 351.4M 459.6M 190.7M
Non-Current Assets 34.4M 45.7M 53.5M 60.2M 64.9M
Total Assets 284.0M 285.9M 404.9M 519.8M 255.6M
Liabilities
Current Liabilities 67.0M 58.4M 55.2M 48.7M 18.8M
Non-Current Liabilities 262.5M 304.7M 349.6M 374.2M 90.6M
Total Liabilities 329.5M 363.1M 404.8M 422.9M 109.4M
Equity
Total Shareholders Equity -45.5M -77.2M 112.0K 96.9M 146.2M

Balance Sheet Composition

Foghorn Therapeutics Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -86.6M -98.4M -108.9M -101.3M -68.8M
Operating Cash Flow -98.9M -114.4M 193.8M -52.5M -29.9M
Investing Activities
Capital Expenditures -906.0K -1.2M -1.2M -3.3M -15.9M
Investing Cash Flow -29.9M 144.4M -244.3M 36.2M -108.9M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow 102.8M - 0 21.0M 216.3M
Free Cash Flow -101.3M -119.3M 192.4M -53.6M -47.5M

Cash Flow Trend

Foghorn Therapeutics Key Financial Ratios

Valuation Ratios

Forward P/E -3.09
Price to Book -5.07
Price to Sales 11.60
PEG Ratio -3.09

Profitability Ratios

Profit Margin 0.00%
Operating Margin -384.96%
Return on Equity 190.26%
Return on Assets -23.12%

Financial Health

Current Ratio 3.16
Debt to Equity -0.57
Beta 3.05

Per Share Data

EPS (TTM) -$1.29
Book Value per Share -$1.11
Revenue per Share $0.39

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
fhtx 272.6M - -5.07 190.26% 0.00% -0.57
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Alpha Tau Medical 245.6M - 3.63 -47.95% 0.00% 21.83
Cartesian 250.0M 1.81 -12.32 1,138.25% -112.11% -0.65
Tevogen Bio Holdings 222.5M 2.86 -24.67 205.68% 0.00% -0.62

Financial data is updated regularly. All figures are in the company's reporting currency.